Digestive Diseases and Sciences

, Volume 59, Issue 10, pp 2571–2579 | Cite as

Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors

  • Man-Man Wang
  • Gong-Sui Wang
  • Feng Shen
  • Guang-Yu Chen
  • Qin Pan
  • Jian-Gao FanEmail author
Original Article


Background and Aims

The interaction between hepatitis B virus (HBV) infection and hepatic steatosis remains unclear. We aimed to explore the trend of prevalence of hepatic steatosis and its relationship with virological factors in HBV infected patients.


Consecutive untreated patients with chronic HBV infection at Shunde Hospital between 2002 and 2011 were included. Quantification of HBV replication markers was performed by enzyme immunoassay, real-time polymerase chain reaction assay and immunohistochemical staining. Hepatic steatosis was defined as at least 5 % hepatocytes affected.


A total of 3,212 patients (2,574 men) with a mean age of 32 ± 9.3 years were analyzed. Serological testing showed detectable HBsAg in all, HBeAg in 63.8 % and HBV DNA in 78.4 % of patients. Liver biopsies demonstrated HBsAg- and HBcAg-positive immunostaining in 96.6 and 71 % patients, respectively. Hepatic steatosis was present in 554 (17.3 %) patients, with annual prevalence increased over time from 8.2 to 31.8 % (trend analysis, x 2 = 51.657, P < 0.001). Compared to patients without steatosis, the percentages of serum HBeAg-positive and detectable HBV DNA, and intrahepatic HBsAg- and HBcAg-positive staining were decreased in steatosis patients (all P < 0.001). Adjusted for age and gender, intrahepatic HBsAg-positive staining remained as an independent factor associated with lower risk of steatosis (adjusted odds ratio 0.90, 95 % confidence interval 0.835, 0.971) in multivariate analysis.


Hepatic steatosis in HBV infected patients has been raging over the past decade, and it is negatively associated with intrahepatic expression of HBsAg. Lifestyle intervention may be needed to halt the onset of steatosis in chronic HBV infection.


Hepatitis B virus Hepatic steatosis Nonalcoholic fatty liver disease Hepatitis B surface antigen Metabolic syndrome 



We wish to thank all patients and medical staff who participated in the study. This work was financially supported by the State Key Development Program for Basic Research of China (2012CB517500), the Program of the Shanghai Committee of Science and Technology (09140903500 &10411956300), the National Natural Science Foundation of China (81070322 &81270491), and the 100 Talents Program of the Shanghai Board of Health (XBR2011007).

Conflict of interest



  1. 1.
    Liu J, Fan D. Hepatitis B in China. Lancet. 2007;369:1582–1583.PubMedCrossRefGoogle Scholar
  2. 2.
    Jia JD, Yao GB. Achieving ultimate control of hepatitis B infection in China: progress and challenges. J Viral Hepat. 2010;17:2–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50:204–210.PubMedCrossRefGoogle Scholar
  4. 4.
    Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–777.PubMedCrossRefGoogle Scholar
  5. 5.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for on-alcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.PubMedCrossRefGoogle Scholar
  6. 6.
    Fan JG, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008;23:679–681.PubMedCrossRefGoogle Scholar
  7. 7.
    Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367.PubMedGoogle Scholar
  8. 8.
    Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol. 2003;9:1106–1110.PubMedGoogle Scholar
  9. 9.
    Shi J, Fan JG, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419–1425.PubMedCrossRefGoogle Scholar
  10. 10.
    Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.PubMedCrossRefGoogle Scholar
  11. 11.
    Rastogi A, Sakhuja P, Kumar A, et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011;54:454–459.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang Z, Pan Q, Duan XY, et al. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol. 2012;27:1858–1864.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang GS, Wang MM, Xie QL, et al. Expression and clinical significance of HBsAg and HBcAg in hepatocytes in chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2004;12:287–289.PubMedGoogle Scholar
  14. 14.
    Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–E468.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim CH, Kallman JB, Bai C, et al. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg. 2010;20:154–160.PubMedCrossRefGoogle Scholar
  16. 16.
    Luo B, Wang Y, Wang K. Association of metabolic syndrome and hepatitis B infection in a Chinese population. Clin Chim Acta. 2007;380:238–240.PubMedCrossRefGoogle Scholar
  17. 17.
    Jan CF, Chen CJ, Chiu YH et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 2006; 30:794–799.Google Scholar
  18. 18.
    Zhang Z, Pan Q, Duan XY, Shi JP, Fan JG. Establishment and identification of non-alcoholic fatty liver disease in chronic hepatitis B virus infected mice. Zhonghua Gan Zang Bing Za Zhi. 2011;19:658–663.PubMedGoogle Scholar
  19. 19.
    Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–266.PubMedCrossRefGoogle Scholar
  20. 20.
    Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus surface antigen in chronic HBV infection? Int J Obes. 2007;31:871–875.Google Scholar
  21. 21.
    Chu CM, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci. 2013;58:275–281.PubMedCrossRefGoogle Scholar
  22. 22.
    Fung J, Yuen MF, Lai CL. The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection: fact or fiction? Dig Dis Sci. 2013;58:20–22.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Lim JK, Nguyen MH. The role of hepatic steatosis in chronic hepatitis B infection. Curr Hepatitis Rep. 2011;10:134–141.CrossRefGoogle Scholar
  24. 24.
    Shi JP, Xun YH, Su YX, et al. Metabolic syndrome and severity of fibrosis in patients with chronic hepatitis B virus infection or nonalcoholic fatty liver disease. J Microbiol Res. 2011;5:481–485.Google Scholar
  25. 25.
    Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–117.PubMedCrossRefGoogle Scholar
  26. 26.
    Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410–1415.PubMedCrossRefGoogle Scholar
  27. 27.
    Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–471.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Takamatsu S, Noguchi N, Kudoh A, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology. 2008;55:609–614.PubMedGoogle Scholar
  29. 29.
    Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933–1944.PubMedCrossRefGoogle Scholar
  30. 30.
    Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol. 2011;55:61–68.PubMedCrossRefGoogle Scholar
  31. 31.
    Lin LY, Wong VW, Zhou HJ, et al. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol. 2010;82:1494–1500.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Man-Man Wang
    • 1
    • 2
  • Gong-Sui Wang
    • 3
  • Feng Shen
    • 1
  • Guang-Yu Chen
    • 1
  • Qin Pan
    • 1
  • Jian-Gao Fan
    • 1
    Email author
  1. 1.Department of Gastroenterology, Xinhua Hospital, Shanghai Key Laboratory of Children’s Digestion and NutritionShanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Department of EndocrinologyThe Third Affiliated Hospital of Sun Yat-Sen UniversityGuangzhouChina
  3. 3.Department of Infectious DiseaseShunde First People’s Hospital Affiliated to Southern Medical UniversityShundeChina

Personalised recommendations